- Home
- ARGX vs ARES Comparison
ARGX vs ARES Comparison
Compare ARGX & ARES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- ARES
- Stock Information
- Founded
- ARGX 2008
- ARES 1997
- Country
- ARGX Netherlands
- ARES United States
- Employees
- ARGX N/A
- ARES N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- ARES Investment Managers
- Sector
- ARGX Health Care
- ARES Finance
- Exchange
- ARGX Nasdaq
- ARES Nasdaq
- Market Cap
- ARGX 37.3B
- ARES 35.3B
- IPO Year
- ARGX 2017
- ARES 2014
- Fundamental
- Price
- ARGX $640.52
- ARES $191.48
- Analyst Decision
- ARGX Strong Buy
- ARES Buy
- Analyst Count
- ARGX 20
- ARES 14
- Target Price
- ARGX $653.11
- ARES $166.38
- AVG Volume (30 Days)
- ARGX 258.1K
- ARES 933.8K
- Earning Date
- ARGX 02-27-2025
- ARES 02-05-2025
- Dividend Yield
- ARGX N/A
- ARES 1.94%
- EPS Growth
- ARGX N/A
- ARES 0.39
- EPS
- ARGX N/A
- ARES 2.19
- Revenue
- ARGX $1,908,659,000.00
- ARES $3,679,765,000.00
- Revenue This Year
- ARGX $70.98
- ARES $0.31
- Revenue Next Year
- ARGX $51.22
- ARES $34.28
- P/E Ratio
- ARGX N/A
- ARES $87.56
- Revenue Growth
- ARGX 85.56
- ARES 4.67
- 52 Week Low
- ARGX $349.86
- ARES $113.66
- 52 Week High
- ARGX $678.21
- ARES $192.01
- Technical
- Relative Strength Index (RSI)
- ARGX 52.90
- ARES 65.51
- Support Level
- ARGX $657.10
- ARES $171.47
- Resistance Level
- ARGX $678.21
- ARES $182.79
- Average True Range (ATR)
- ARGX 15.00
- ARES 4.51
- MACD
- ARGX 0.45
- ARES 0.92
- Stochastic Oscillator
- ARGX 42.20
- ARES 97.42
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
About ARES Ares Management Corporation
Ares Management Corp is an asset management company. It offers investors investment-related advice and strategies for capital growth. The company's operating segments include Credit Group, Private Equity Group, Real Assets and Secondaries Group. Its Credit Group generates maximum revenue, and manages credit strategies across the liquid and illiquid spectrum. Private Equity Group manages investment strategies categorized as corporate private equity, infrastructure and power, and special opportunities, Real Estate Group manages comprehensive equity and debt strategies across real estate and infrastructure investments. The Secondaries Group invests in secondary markets across a range of alternative asset class strategies, including private equity, real estate, infrastructure and credit.